Ikechukwu Ibegbu, MD
Gastroenterology · Jacksonville, NCNPI 1639154248
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,150 of the $10,203 with a category attached, or 60.3%. 33 manufacturers reported payments, led by Apollo Endosurgery US Inc at 59.0% of the total. Reporting peaked in 2019 at $6,185 and has fallen 86.9% since, to $813 in 2025.
Across 213 payments — averaging $47.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apollo Endosurgery US Inc$6K
- AbbVie$700
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$599
- Boston Scientific$484
- Palette Life Sciences, Inc.$450
- Ardelyx, Inc.$338
- plus $2K from 27 others
Across 39 payments — averaging $40,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.5M
- Bristol Myers Squibb$43K
- Janssen Research & Development, LLC$29K
- Regeneron$21K
- Genentech, Inc.$350
What the payments were for
- Consulting fees$6,15060%
- Speaking & faculty fees$2002%
- Food & beverage$3,78637%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apollo Endosurgery US Inc | 9 | $6,021 |
| AbbVie(2 entities) | 36 | $700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $599 |
| Boston Scientific | 5 | $484 |
| Palette Life Sciences, Inc. | 1 | $450 |
| Ardelyx, Inc. | 17 | $338 |
| Pfizer | 15 | $213 |
| Ironwood Pharmaceuticals, Inc | 11 | $174 |
| Nestle Healthcare Nutrition Inc. | 10 | $163 |
| Johnson & Johnson(2 entities) | 6 | $159 |
| Gilead | 9 | $130 |
| Phathom Pharmaceuticals, Inc. | 4 | $78 |
| Amgen | 4 | $68 |
| Laborie Medical Technologies Corp. | 4 | $67 |
| Intercept Pharmaceuticals, Inc. | 5 | $66 |
| Currax Pharmaceuticals LLC | 5 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $46 |
| Nalpropion Pharmaceuticals LLC | 3 | $41 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Capsovision, Inc. | 1 | $34 |
| Redhill Biopharma Inc. | 2 | $30 |
| Braintree Laboratories, Inc. | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Ambu Inc. | 1 | $18 |
| Mauna Kea Technologies, Inc. | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
| QOL Medical, LLC | 1 | $12 |
| Merck | 1 | $12 |
| Vivus LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orbera$5,700
- Solesta$450
- OverStitch Endoscopic Suturing System$279
- LINZESS$200
- SPYGLASS$141
- ORBERA Intragastric Balloon System$129
How this compares
$10,203 in reported general payments places this provider in the 80th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 122 | $99,718 |
| ZenpepLipase/Protease/Amylase | 18 | $70,003 |
| CreonLipase/Protease/Amylase | 14 | $33,608 |
| Dexlansoprazole DrDexlansoprazole | 58 | $12,927 |
| Mesalamine | 30 | $10,645 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 252 | $4,220 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 21 | $3,500 |
| Pantoprazole Sodium | 465 | $3,205 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 115 | $1,897 |
| Dicyclomine Hcl | 71 | $1,830 |
| Balsalazide Disodium | 12 | $1,573 |
| Lubiprostone | 23 | $1,498 |
| Omeprazole | 62 | $1,055 |
| Ondansetron OdtOndansetron | 24 | $709 |
| Esomeprazole Magnesium | 29 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $700 | $133,326136 claims |
| Aimmune Therapeutics, Inc.Zenpep | $20 | $70,00318 claims |
| Braintree Laboratories, Inc.Sutab | $30 | $3,50021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Jacksonville
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
- Manal AbdelmalekDurham$402K
- Christopher McGowanCary$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.